Tri-sprintec and Magnesium drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tri-sprintec (ethinyl estradiol; norgestimate) and Magnesium (magnesium). Common drug interactions include nausea among females.

The phase IV clinical study analyzes what interactions people have when they take Tri-sprintec and Magnesium. It is created by eHealthMe based on reports of 17 people who take the same drugs from the FDA, and is updated regularly.

What is Tri-sprintec?

Tri-sprintec has active ingredients of ethinyl estradiol; norgestimate. It is often used in birth control. eHealthMe is studying from 1,428 Tri-sprintec users. Check the latest studies of Tri-sprintec.

What is Magnesium?

Magnesium has active ingredients of magnesium. It is often used in constipation. eHealthMe is studying from 121,144 Magnesium users. Check the latest studies of Magnesium.

On Jul, 19, 2026

17 people who take Tri-sprintec and Magnesium together, and have interactions are studied.

Tri-sprintec and Magnesium drug interactions.

What are the common drug interactions of Tri-Sprintec and Magnesium, by gender? *:

female:

Nausea (feeling of having an urge to vomit)
Rash
Cystitis (inflammation of the wall of the bladder)
Dehydration (dryness resulting from the removal of water)
Dizziness
Erythema (redness of the skin)
Gastritis (inflammation of stomach)
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Hypotension (abnormally low blood pressure)
Injection site erythema (redness at injection site)

male:

n/a

What are the common drug interactions of Tri-Sprintec and Magnesium, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Abdominal pain upper
Bruxism (habitual grinding of the teeth, typically during sleep)
Burning sensation
Cough
Dissociation
Drug ineffective
Dyspepsia (indigestion)
Headache (pain in head)
Hypophagia (reduced food intake)
Nausea (feeling of having an urge to vomit)

30-39:

Injection site erythema (redness at injection site)
Injection site pain
Injection site pruritus (severe itching at injection site)
Injection site swelling
Nausea (feeling of having an urge to vomit)
Skin lesion
Somnolence (a state of near-sleep, a strong desire for sleep)
Dyspnoea (difficult or laboured respiration)
Flushing (the warm, red condition of human skin)
Hypocalcaemia (levels of calcium in blood serum are abnormally low)

40-49:

Nausea (feeling of having an urge to vomit)
Psoriasis (immune-mediated disease that affects the skin)
Rash
Thrombosis (formation of a blood clot inside a blood vessel)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 5 people, 29.41%
Neurodermatitis (a skin disorder characterized by long lasting itching and scratching): 3 people, 17.65%
Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 3 people, 17.65%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 2 people, 11.76%
Behcet's Syndrome (involves inflammation of the blood vessels): 2 people, 11.76%
Thyroid Cancer: 1 person, 5.88%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 5.88%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 5.88%
Hypocalcaemia (levels of calcium in blood serum are abnormally low): 1 person, 5.88%
Gait Disturbance: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Tri-sprintec and Magnesium?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously